Now Reading: US FDA flags Aurobindo arm AuroPeptides plant near Hyderabad
-
01
US FDA flags Aurobindo arm AuroPeptides plant near Hyderabad
The US Food and Drug Administration has issued one observation to AuroPeptides, the peptide API manufacturing subsidiary of Aurobindo Pharma, after a routine inspection of its facility in Sangareddy district near Hyderabad…
The US Food and Drug Administration has issued one observation to AuroPeptides, the peptide API manufacturing subsidiary of Aurobindo Pharma, after a routine inspection of its facility in Sangareddy district near Hyderabad from August 17 to 21.
The observation pertains to facility and equipment maintenance and does not relate to data integrity or Good Manufacturing Practice compliance, the company said. Corrective action was initiated during the inspection, and a formal response will be submitted within the stipulated timeline, Aurobindo Pharma said in a stock exchange filing on Friday.
Indian Opinion Analysis
The single observation is a relatively minor regulatory outcome, avoiding data integrity issues that often lead to warning letters or import alerts. Aurobindo's shares may see limited impact unless the FDA escalates after reviewing the response. The next signal to watch is whether the FDA closes the observation or issues a follow-up within 90 days.
Source: thehindu.com
This story was synthesised by AI from the source linked above.
